Seeking Alpha
Sign in
PRO
MARKETPLACE
SUBSCRIBE
Premium
Premium Overview
Compare Stocks & Funds
Notable Calls
News Dashboard
Top Rated Stocks
Top Dividend Stocks
Top REITs
Top Growth Stocks
My Portfolio
All Portfolios
+ Create Portfolio
Manage Email Summary
Manage Real Time Email Alerts
My Authors
My Authors
Author Email Alerts
Top Stocks
Ratings Screener
ETF Screener
Latest News
Latest News
Notable Calls
On The Move
Top News
Wall Street Breakfast
IPO News
M&A News
U.S. Economy
Tech News
Energy News
Healthcare News
Crypto News
Top Movers on Earnings
Earnings News
Earnings Calendar
See All Sections »
Markets
Market Outlook
Today’s Market
Economy
Gold and Precious Metals
Commodities
Forex
Real Estate
Editors Picks
Cryptocurrencies
Global Investing Center
Stock Ideas
Long Ideas
IPO Analysis
Quick Picks and Lists
Fund Letters
Closed End Funds
Stock Ideas by Sector
Stock Ideas Editors Picks
Short Ideas
Dividends
Dividend Ideas
Dividend News
REITs
Dividend Strategy
Dividend Quick Picks
Dividend ETFs
Real Estate ETFs
Dividend Editors Picks
Fixed Income
Retirement
ETFs
ETF Analysis
ETF Screener
Editors' Picks
Let’s Talk ETFs
ETF Performance - Sectors
ETF Performance - Countries
ETF Performance - Market Cap
Investing Strategy
Investing Strategy
Editors' Picks
Portfolio Strategy
Financial Advisor
Watch & Listen
Podcasts
Videos
Help & Support
Knowledge Base
Feedback Forum
Graham Osborn
Edit Profile
I no longer publish on SeekingAlpha.
Contributor since:
2015
Company:
Website
Twitter
LinkedIn
RSS Feed
Send Message
Graham Osborn
Save Changes
Cancel
I no longer publish on SeekingAlpha.
Contributor since:
2015
Value, Special Situations, Long/Short Equity, Contrarian
Company:
Company
Website URL
Website Name
LinkedIn
Twitter
8
Articles
1
Author's Picks
132
Comments
1
Likes
179
Followers
73
Following
Filter By Ticker
All
(8)
Top Ideas
(0)
Editors' Picks
(4)
Filter By Ticker
Filter By Ticker
Filter By Ticker
All
(1)
Articles
(0)
Blogs
(0)
Comments
(1)
Filter By Ticker
All
(0)
Articles
A Prescription For Teva Shareholders On Actavis Generics
Editors' Pick
Jun. 24, 2016
TEVA
,
AGN
36 Comments
A Valeant Effort: How Allergan Used Acquisition Accounting To Inflate Sales Growth, Boost NOLs, And Reinvent The Operating Profitability Of Actavis Generics
Editors' Pick
Jun. 20, 2016
AGN
80 Comments
Actavis Generics: A 2-Year Ticket To Insolvency?
Editors' Pick
May 23, 2016
TEVA
,
AGN
61 Comments
A Prescription For Valeant
Nov. 5, 2015
BHC
67 Comments
JACK: Thinking Outside The Box
Editors' Pick
Oct. 15, 2015
JACK
2 Comments
AmerisourceBergen: Already Been Chewed?
Sep. 23, 2015
ABC
4 Comments
Valuing Valeant
Aug. 18, 2015
BHC
26 Comments
Historical Comparables For Facebook
Apr. 13, 2015
FB
33 Comments
COMMENTS STATS
132
84
Don't miss any articles by
Graham Osborn
Join Seeking Alpha to get real-time alerts on your favorite authors.